Zhangzhou Pientzehuang Pharmaceutical Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Jin Ming Huang

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	5.3yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	5.3yrs

Recent management updates

Recent updates

CEO

Jin Ming Huang (58 yo)

5.3yrs

Tenure

CN¥601,700

Compensation

Mr. Jin Ming Huang is GM & Director of Zhangzhou Pientzehuang Pharmaceutical., Ltd from July 2019. He joined the Zhangzhou Pientzehuang Pharmaceutical., Ltd in September 2006. Mr. Huang served as President...

Board Members

Name	Position	Tenure	Compensation	Ownership
Jin Ming Huang	GM & Director	5.3yrs	CN¥601.70k	no data
Haipeng Yang	Chief Accountant & Director	no data	CN¥529.50k	no data
Cong Sheng Liu	Deputy GM & Director	no data	CN¥529.50k	no data
Jin Cheng Chen	Chairman of the Supervisory Committee	2.4yrs	CN¥207.60k	no data
Jianjun Jia	Independent Director	7.3yrs	CN¥80.00k	no data
Dong Ming Hong	Director	no data	CN¥444.50k	no data
Guang Pei Li	Independent Director	7.3yrs	CN¥80.00k	no data
Zhi Peng Fan	Independent Director	6.7yrs	CN¥80.00k	no data
Tengyun Wei	Supervisor	2.8yrs	no data	no data
Hong Kai Xu	Member of the Supervisory Board	7.2yrs	no data	no data
Shouying Du	Independent Director	2.8yrs	CN¥80.00k	no data
Huang Yalong	Employee Supervisor	2.8yrs	no data	no data

5.3yrs

Average Tenure

56.5yo

Average Age

Experienced Board: 600436's board of directors are considered experienced (5.3 years average tenure).

Zhangzhou Pientzehuang Pharmaceutical Management

Management criteria checks 2/4

Key information

Recent management updates

Zhangzhou Pientzehuang Pharmaceutical., Ltd, Annual General Meeting, May 20, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥1.60 (vs CN¥1.44 in 3Q 2023)

Investor sentiment deteriorates as stock falls 16%

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q3, 2024 Results on Oct 19, 2024

Investor sentiment improves as stock rises 17%

New minor risk - Dividend sustainability

Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) agreed to acquire Zhangzhou Mingyuan Spice Co., Ltd. from Zhangzhou State-owned Asset Investment Management Co., Ltd. for approximately CNY 250 million.

Second quarter 2024 earnings released: EPS: CN¥1.23 (vs CN¥1.27 in 2Q 2023)

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report First Half, 2024 Results on Aug 17, 2024

Zhangzhou Pientzehuang Pharmaceutical., Ltd, Annual General Meeting, May 20, 2024

First quarter 2024 earnings released: EPS: CN¥1.62 (vs CN¥1.28 in 1Q 2023)

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q1, 2024 Results on Apr 20, 2024

Full year 2023 earnings released: EPS: CN¥4.61 (vs CN¥4.10 in FY 2022)

Now 21% undervalued after recent price drop

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Fiscal Year 2023 Results on Apr 20, 2024

Third quarter 2023 earnings released: EPS: CN¥1.44 (vs CN¥1.22 in 3Q 2022)

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q3, 2023 Results on Oct 21, 2023

Second quarter 2023 earnings released: EPS: CN¥1.27 (vs CN¥1.04 in 2Q 2022)

Second quarter 2023 earnings released: EPS: CN¥1.26 (vs CN¥1.04 in 2Q 2022)

Investor sentiment improves as stock rises 15%

First quarter 2023 earnings released: EPS: CN¥1.28 (vs CN¥1.14 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥4.09 (vs CN¥4.03 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥1.22 (vs CN¥1.48 in 3Q 2021)

Now 21% undervalued after recent price drop

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥4.03 (vs CN¥2.77 in FY 2020)

Now 23% undervalued after recent price drop

Third quarter 2021 earnings released: EPS CN¥1.48 (vs CN¥0.77 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.91 (vs CN¥0.65 in 2Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.91 (vs CN¥0.65 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.94 (vs CN¥0.78 in 1Q 2020)

New 90-day high: CN¥326

Revenue misses expectations

Revenue misses expectations

Full year 2020 earnings released: EPS CN¥2.76

New 90-day high: CN¥300

New 90-day high: CN¥252

New 90-day low: CN¥212

Third quarter earnings released

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report Q3, 2020 Results on Oct 24, 2020

New 90-day high - CN¥208

Earnings released

Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) agreed to acquire 29.2% stake in Longhui Pharmaceutical Co., Ltd. from Longhui Group Co., Ltd. and Jinyuan Rongtai Investment Management (Ningxia) Co., Ltd.

Zhangzhou Pientzehuang Pharmaceutical., Ltd to Report First Half, 2020 Results on Aug 22, 2020

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age